Sex differences in self-rated health and cardiovascular disease events
Sud M, Qiu F, Haldenby O, Islam S, Austin PC, Manuel D, Eurich D, Kaul P, Graham MM, Madan M, Huynh T, Spatz ES, Wijeysundera HC, Ko DT. JAMA Netw Open. 2026; 9(4): e264129.
Aims — To determine what proportion of patients with heart failure are eligible for cardiac resynchronization therapy (CRT).
Methods and Results — Eligibility criteria from the trials establishing the efficacy of CRT were applied to two prospective cohorts: the first enrolled patients with newly diagnosed heart failure discharged from 103 hospitals between April 1999 and March 2001 (‘the hospital discharge cohort’); the second enrolled patients seen in a specialized clinic between August 2003 and January 2004 (‘the specialty clinic cohort’). In the hospital discharge cohort, 73 patients (3% of the 2640 patients with ischaemic or dilated cardiomyopathy and 1% of all 9096 patients with heart failure discharged alive) met trial eligibility criteria: LVEF≤0.35, QRS ≥120 ms, sinus rhythm, and NYHA class III or IV symptoms despite the treatment with ACE-inhibitor/angiotensin receptor blocker and beta-blocker. In the specialty clinic cohort, 54 patients (21% of the 263 patients with ischaemic or dilated cardiomyopathy and 17% of all 309 patients with heart failure) met these criteria. If persistent symptoms despite taking spironolactone were required for CRT eligibility, then the proportions qualifying dropped to 1% in the hospital discharge cohort and 18% in the specialty clinic cohort.
Conclusion — Few heart failure patients meet trial eligibily criteria for CRT.
McAlister FA, Tu JV, Newman A, Lee DS, Kimber S, Cujec B, Armstrong PW. Eur Heart J. 2006; 27(3):323-9. Epub 2005 Aug 16.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.